Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
With a market cap of 5.43B, Alkermes(ALKS) trades at $32.89. The stock has a price-to-earnings ratio of 16.27.
On 2025-11-09, Alkermes(ALKS) stock moved within a range of $31.41 to $32.95. With shares now at $32.89, the stock is trading +4.7% above its intraday low and -0.2% below the session's peak.
Trading volume for Alkermes(ALKS) stock has reached 1.99M, versus its average volume of 3.04M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
In the third quarter of 2025, Alkermes reported revenue of US$394.19 million and net income of US$82.76 million, alongside updates on its share repurchase progr...
Investors in Alkermes plc (Symbol: ALKS) saw new options begin trading today, for the January 2028 expiration. One of the key data points that goes into the pri...
RBC Capital analyst Leonid Timashev notes Centessa (CNTA) reported Phase 2a data from initial dosing cohorts in a study of ORX750 in narcolepsy type 1 patients...
Analyst ratings
80%
of 15 ratingsMore ALKS News
Stifel expects shares of Alkermes (ALKS) to move higher on the narcolepsy type 1 data reported by Centessa (CNTA). The initial clinical disclosure from Centessa...